GO:0031841 neuropeptide Y receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031841 (neuropeptide Y receptor binding) is a molecular function defined as binding to a neuropeptide Y receptor.
• The term encompasses interactions of NPY-family peptides (NPY, PYY, PP) with Y1, Y2, Y4, Y5 receptors, which are class A GPCRs.
• Structural studies reveal that NPY binds Y1 and Y2 receptors through a two-step mechanism involving the receptor N-terminus and extracellular loops.
• Ligand binding to Y receptors is regulated by allosteric pockets and transient contacts, influencing arrestin recruitment and signaling bias.
• Dysregulation of NPY receptor binding is implicated in cancer, obesity, and cardiovascular disorders, making it a therapeutic target.
• CRISPR-based models (KO, point mutation, knock-in) enable precise dissection of NPY receptor binding and downstream signaling.
Description
Neuropeptide Y (NPY) receptor binding (GO:0031841) is a molecular function that mediates the interaction between NPY-family peptides and their cognate G protein-coupled receptors (GPCRs). This binding event is the first step in a signaling cascade that regulates diverse physiological processes, including food intake, energy homeostasis, circadian rhythms, and cardiovascular function. The NPY system comprises three endogenous peptide ligands—NPY, peptide YY (PYY), and pancreatic polypeptide (PP)—and four functional receptor subtypes in humans: Y1, Y2, Y4, and Y5. Each receptor exhibits distinct binding preferences and tissue distribution, enabling fine-tuned physiological responses. Understanding the molecular details of NPY receptor binding is critical for drug discovery, as these receptors are targets for obesity, cancer, and neurological disorders. Recent structural and biochemical studies have elucidated the binding modes of natural and synthetic ligands, revealing conformational changes and allosteric modulation that govern receptor activation. This article synthesizes current knowledge on GO:0031841, covering its definition, mechanism, key genes, disease relevance, and research methodologies.
neuropeptide Y receptor binding At A Glance
| GO ID | GO:0031841 |
|---|---|
| GO term | neuropeptide Y receptor binding |
| Ontology | molecular_function |
| Synonym | neuropeptide Y receptor ligand; NPY receptor binding |
| Definition | Binding to a neuropeptide Y receptor. |
| Major function | Mediates ligand-receptor interaction for NPY-family peptides with Y1, Y2, Y4, Y5 receptors. |
| Related receptors | NPY1R, NPY2R, NPY4R, NPY5R |
| Related ligands | NPY, PYY, PP |
| Signaling pathway | Gi/o-coupled GPCR signaling, inhibition of adenylyl cyclase, modulation of ion channels. |
What Is GO:0031841?
GO:0031841 (neuropeptide Y receptor binding) is defined by the Gene Ontology as the binding to a neuropeptide Y receptor. It describes the molecular function of a ligand (typically a peptide such as NPY, PYY, or PP) that selectively interacts with one or more NPY receptor subtypes (Y1, Y2, Y4, Y5). This binding is non-covalent and reversible, and it initiates receptor conformational changes that lead to intracellular signaling.
Why Is neuropeptide Y receptor binding Important in Cell Biology?
Neuropeptide Y receptor binding is a central molecular event in neuroendocrine regulation, controlling appetite, energy balance, stress responses, and cardiovascular tone. Dysregulated NPY signaling contributes to obesity, cancer progression, and mood disorders, making this binding function a prime target for therapeutic intervention. Structural insights into ligand binding have accelerated the design of subtype-selective drugs with improved efficacy and reduced side effects.
• Regulates food intake and energy homeostasis via hypothalamic Y1 and Y5 receptors.
• Modulates cardiovascular function, including vasoconstriction and angiogenesis.
• Implicated in cancer cell proliferation and migration, particularly in breast and prostate cancers.
• Influences anxiety, depression, and stress responses through limbic system Y2 receptors.
• Serves as a target for anti-obesity drugs (e.g., Y2/Y4 agonists) and anti-cancer agents.
• Provides a paradigm for understanding peptide-GPCR binding specificity and allostery.
• Key to developing PET tracers for imaging NPY receptor expression in vivo.
• Relevant to circadian rhythm regulation and sleep-wake cycles.
• Contributes to bone remodeling and gastrointestinal motility.
• Enables precision medicine approaches targeting receptor subtypes in metabolic diseases.
Molecular Mechanism of neuropeptide Y receptor binding
Ligand recognition and initial contact
In simple terms: The NPY peptide first touches the receptor's outer surface.
NPY-family peptides are 36-amino-acid polypeptides with a hairpin-like fold. Binding to Y receptors begins with electrostatic interactions between the peptide's C-terminal arginine and conserved acidic residues in the receptor's extracellular loops. For Y2 receptor, the intrinsically disordered N-terminus makes transient contacts that guide the ligand into the binding pocket.
Two-step binding and conformational change
In simple terms: The peptide inserts deeper, causing the receptor to change shape.
Structural studies of Y1 and Y2 receptors reveal a two-step mechanism: first, the peptide's C-terminal segment binds to the receptor core; second, the N-terminal region of the peptide interacts with the receptor N-terminus, inducing a conformational shift in transmembrane helix 6 that opens the G-protein coupling interface. This rearrangement is essential for signal transduction.
Allosteric modulation and subtype selectivity
In simple terms: Other molecules can bind elsewhere on the receptor to tweak its activity.
The Y4 receptor possesses an allosteric pocket that binds synthetic antagonists, altering the receptor's affinity for NPY. Similarly, Y5 receptor binding is influenced by natural peptide ligands that occupy distinct sub-pockets, contributing to subtype selectivity. These allosteric sites offer opportunities for designing biased ligands.
Arrestin recruitment and signaling bias
In simple terms: After binding, the receptor can recruit different partners to send specific signals.
Ligand binding stabilizes distinct receptor conformations that differentially recruit arrestin-3. For Y2 receptor, transient contacts of the N-terminus regulate arrestin-3 recruitment, affecting downstream ERK signaling. This biased agonism is critical for physiological outcomes such as appetite suppression versus anxiety.
Regulation by receptor interactions
In simple terms: Receptors can team up with each other to change binding behavior.
Y1 and Y5 receptors can form heterodimers, which alters their binding affinity and mitogenic activity. Such interactions modulate NPY-induced proliferation in cancer cells, highlighting the importance of receptor context in binding function.
Key Genes Involved in GO:0031841 neuropeptide Y receptor binding
The following genes encode the receptors and ligands that participate in neuropeptide Y receptor binding (GO:0031841).
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPY | Endogenous ligand for Y1, Y2, Y5 receptors | Central to appetite and stress studies; KO models show obesity resistance |
| PYY | Ligand with high affinity for Y2 receptor | Regulates satiety; used in obesity research |
| PP | Pancreatic polypeptide, prefers Y4 receptor | Involved in energy metabolism; Y4 agonist studies |
| NPY1R | Y1 receptor, mediates food intake and vasoconstriction | Target for anti-obesity and anti-hypertensive drugs |
| NPY2R | Y2 receptor, inhibits neurotransmitter release | Key for satiety signaling; structural studies |
| NPY4R | Y4 receptor, regulates pancreatic secretion | Allosteric antagonist binding studied |
| NPY5R | Y5 receptor, modulates feeding and seizure threshold | Ligand binding studies for epilepsy |
| ARRB1 | Beta-arrestin 1, downstream effector | Mediates receptor desensitization |
| ARRB2 | Beta-arrestin 2, downstream effector | Regulates ERK signaling |
| GNAI1 | Gi alpha subunit, inhibits adenylyl cyclase | Couples to Y receptors for signaling |
| GNAO1 | Go alpha subunit, modulates ion channels | Neuronal signaling downstream of Y2 |
| GRK2 | G protein-coupled receptor kinase 2 | Phosphorylates activated Y receptors |
| GRK5 | G protein-coupled receptor kinase 5 | Involved in Y1 desensitization |
| PRKCA | Protein kinase C alpha | Modulates Y receptor phosphorylation |
| SRC | Proto-oncogene tyrosine-protein kinase Src | Mediates mitogenic signaling from Y1/Y5 |
| MAPK1 | Mitogen-activated protein kinase 1 (ERK2) | Downstream of Y receptor activation |
| MAPK3 | Mitogen-activated protein kinase 3 (ERK1) | Downstream of Y receptor activation |
How Is neuropeptide Y receptor binding Regulated?
Neuropeptide Y receptor binding is regulated at multiple levels. Receptor phosphorylation by GRK2/5 and subsequent arrestin recruitment desensitize the receptor, reducing binding affinity. Allosteric modulators can enhance or inhibit ligand binding, as seen for Y4 receptor antagonists. Heterodimerization between Y1 and Y5 receptors alters binding kinetics and downstream signaling. Additionally, the intrinsically disordered N-terminus of Y2 receptor makes transient contacts that regulate arrestin-3 recruitment, providing a dynamic regulatory mechanism.
neuropeptide Y receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPY1R | Breast cancer, hypertension | KO mice, point-mutation knock-in for binding affinity |
| NPY2R | Obesity, anxiety | Conditional KO, overexpression in hypothalamus |
| NPY5R | Epilepsy, obesity | CRISPR knock-in of human variant, tagged receptor |
| NPY | Metabolic syndrome, cancer | Overexpression transgenic, KO |
| PYY | Obesity, irritable bowel syndrome | Knock-in of PYY analogs, KO |
Cancer
NPY receptor binding promotes mitogenic signaling in various cancers. Y1 and Y5 receptor heterodimers enhance NPY-induced proliferation in breast cancer cells, and elevated NPY levels correlate with tumor progression. Targeting these binding interactions with antagonists reduces cancer cell growth in preclinical models.
Obesity and metabolic disorders
Hypothalamic Y1 and Y5 receptor binding stimulates food intake, while Y2 receptor binding inhibits it. Dysregulation of NPY/PYY binding contributes to obesity and metabolic syndrome. Y2 agonists are being developed as anti-obesity therapeutics.
Cardiovascular diseases
NPY binding to Y1 receptors causes vasoconstriction and vascular smooth muscle proliferation, implicating it in hypertension and atherosclerosis. Y1 antagonists are explored for cardiovascular protection.
Neurological and psychiatric disorders
Altered NPY receptor binding in the limbic system is associated with anxiety, depression, and epilepsy. Y2 receptor binding modulates neurotransmitter release, affecting seizure susceptibility. PET tracers targeting Y receptors are used to image these disorders.
From neuropeptide Y receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Y1 receptor binding mediate food intake? | NPY1R KO mice, point mutation of binding pocket |
| How does Y2 receptor allostery affect arrestin recruitment? | Knock-in of Y2 N-terminus mutants, BRET assays |
| What is the role of Y5 receptor in epilepsy? | NPY5R KO rats, overexpression in hippocampus |
| Can Y4 receptor antagonists treat obesity? | Y4 receptor knock-in with humanized allosteric pocket |
| Does NPY promote cancer via Y1/Y5 heterodimers? | Cancer cell lines with double KO of NPY1R/NPY5R |
| How does PYY binding affect satiety? | PYY KO mice, knock-in of PYY analogs |
How to Study the neuropeptide Y receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor affinity (Kd, Bmax) | Subtype selectivity profiling |
| Cryo-EM | 3D structure of ligand-receptor complex | Mechanistic insight into binding |
| BRET | Protein-protein interactions (arrestin, G-protein) | Real-time signaling dynamics |
| CRISPR screen | Gene essentiality for binding | Discovery of novel modulators |
| Surface plasmon resonance | Binding kinetics (kon, koff) | Ligand optimization |
| Flow cytometry | Cell surface receptor expression | Knockout validation |
| Immunoprecipitation | Receptor-ligand complexes | Co-factor identification |
Radioligand binding assays
Competitive binding assays using 125I-labeled NPY or PYY measure receptor affinity and subtype selectivity. These are standard for characterizing NPY receptor binding.
Structural biology (cryo-EM and X-ray crystallography)
Cryo-EM structures of Y1 and Y2 receptors bound to NPY/PYY reveal detailed binding interfaces and conformational changes. These methods guide rational drug design.
BRET and FRET biosensors
Bioluminescence resonance energy transfer (BRET) assays detect arrestin recruitment and G-protein activation in live cells, enabling real-time monitoring of binding-induced signaling.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens identify genes that modulate NPY receptor binding and downstream signaling, uncovering novel regulators.
How CRISPR Can Be Used to Study GO:0031841 neuropeptide Y receptor binding
Knockout
CRISPR knockout of NPY1R, NPY2R, NPY4R, or NPY5R eliminates receptor expression, allowing assessment of ligand binding specificity and downstream effects. For example, NPY1R KO mice show reduced food intake.
Point Mutation
Introducing point mutations in the receptor binding pocket (e.g., Y1 receptor D194A) disrupts NPY binding without affecting surface expression, enabling precise mapping of interaction residues.
Knock-in
Knock-in of human receptor variants or tagged receptors (e.g., HA-tagged Y2) facilitates affinity purification and imaging of binding complexes in vivo.
Overexpression
Overexpression of NPY or its receptors in cell lines or transgenic animals enhances binding signals, useful for studying saturable binding kinetics and drug screening.
How EDITGENE Supports neuropeptide Y receptor binding Research
Researchers studying neuropeptide Y receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream signaling. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell and animal models, accelerating functional validation and therapeutic development.
Contact EDITGENE today to design your custom CRISPR model for neuropeptide Y receptor binding research.
Frequently Asked Questions About neuropeptide Y receptor binding
What is neuropeptide Y receptor binding?
Neuropeptide Y receptor binding (GO:0031841) is the molecular function of a ligand (such as NPY, PYY, or PP) binding to a neuropeptide Y receptor (Y1, Y2, Y4, Y5).
What genes are involved in neuropeptide Y receptor binding?
Key genes include NPY, PYY, PP (ligands) and NPY1R, NPY2R, NPY4R, NPY5R (receptors), as well as downstream effectors like ARRB1/2 and GNAI1.
How does NPY bind to its receptor?
NPY binds via a two-step mechanism: initial electrostatic contact with extracellular loops, followed by insertion into the transmembrane pocket, inducing conformational changes.
What are the subtypes of neuropeptide Y receptors?
There are four functional subtypes in humans: Y1 (NPY1R), Y2 (NPY2R), Y4 (NPY4R), and Y5 (NPY5R).
What diseases are associated with NPY receptor binding?
Dysregulation is linked to obesity, cancer, cardiovascular diseases, and neurological disorders like anxiety and epilepsy.
How can CRISPR be used to study NPY receptor binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of receptor genes to study binding affinity and signaling.
What methods measure NPY receptor binding?
Radioligand binding assays, cryo-EM, BRET, and surface plasmon resonance are commonly used.
Is NPY receptor binding a drug target?
Yes, Y1, Y2, Y4, and Y5 receptors are targets for anti-obesity, anti-cancer, and cardiovascular drugs.
What is the role of allosteric modulation in NPY receptor binding?
Allosteric modulators bind outside the orthosteric site to alter receptor affinity or efficacy, as seen for Y4 receptor antagonists.
How does NPY receptor binding affect food intake?
Binding to hypothalamic Y1 and Y5 receptors stimulates food intake, while Y2 receptor binding inhibits it.
Conclusion
Neuropeptide Y receptor binding (GO:0031841) is a fundamental molecular function that governs diverse physiological and pathological processes through the interaction of NPY-family peptides with Y1, Y2, Y4, and Y5 receptors. Structural and biochemical studies have revealed intricate binding mechanisms, including two-step recognition, allosteric modulation, and biased signaling. These insights have propelled drug discovery efforts targeting NPY receptors for obesity, cancer, and neurological disorders. Continued research using CRISPR-based models and advanced structural techniques will further unravel the complexities of this binding function and facilitate the development of subtype-selective therapeutics.
References
- 1. Wan CP et al.. 1995. Neuropeptide Y receptor subtypes.. Life Sci 56(13):1055-64 PMID: 9001438
- 2. Rudolf S et al.. 2022. Binding of Natural Peptide Ligands to the Neuropeptide Y(5) Receptor.. Angew Chem Int Ed Engl 61(5):e202108738 PMID: 34822209
- 3. Park C et al.. 2022. Structural basis of neuropeptide Y signaling through Y1 receptor.. Nat Commun 13(1):853 PMID: 35165283
- 4. Kang H et al.. 2023. Structural basis for Y2 receptor-mediated neuropeptide Y and peptide YY signaling.. Structure 31(1):44-57.e6 PMID: 36525977
- 5. Czarnecka M et al.. 2019. Neuropeptide Y receptor interactions regulate its mitogenic activity.. Neuropeptides 73:11-24 PMID: 30503694
- 6. Kaiser A et al.. 2025. Transient ligand contacts of the intrinsically disordered N-terminus of neuropeptide Y(2) receptor regulate arrestin-3 recruitment.. Nat Commun 16(1):8326 PMID: 40973726
- 7. Schüß C et al.. 2021. Highly Selective Y(4) Receptor Antagonist Binds in an Allosteric Binding Pocket.. J Med Chem 64(5):2801-2814 PMID: 33595306
- 8. Mittapalli GK et al.. 2014. Ligands of the neuropeptide Y Y2 receptor.. Bioorg Med Chem Lett 24(2):430-41 PMID: 24365162
